Posterior reversible encephalopathy associated with pembrolizumab

Neurologia (Engl Ed). 2021 Sep;36(7):548-550. doi: 10.1016/j.nrleng.2020.08.014. Epub 2021 Jun 23.

Authors

Á Lambea-Gil¹, A Sancho-Saldaña², R Caldú-Agud², S García-Rubio²

Affiliations

¹ Servicio de Neurología, Hospital Universitario Miguel Servet, Zaragoza, Spain. Electronic address: [email protected].
² Servicio de Neurología, Hospital Universitario Miguel Servet, Zaragoza, Spain.

PMID: 34172405
DOI: 10.1016/j.nrleng.2020.08.014

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Brain Diseases*
Humans
Posterior Leukoencephalopathy Syndrome* / chemically induced

Substances

Antibodies, Monoclonal, Humanized
pembrolizumab